Liraglutide Up For Approval In U.S. And Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo Nordisk’s type 2 diabetes drug could face hurdles once longer-acting GLP-1s hit the market.
You may also be interested in...
Novo Nordisk, Emisphere Collaborate To Propel Oral GLP-1 Compounds In R&D
Emisphere carrier technology may be applied to other compounds as well.
Novo Nordisk, Emisphere Collaborate To Propel Oral GLP-1 Compounds In R&D
Emisphere carrier technology may be applied to other compounds as well.
Roche/Ipsen Plan 2010 Filing For Once-Weekly GLP-1 Analog
Phase III studies pitting once-weekly taspoglutide against Lilly's Byetta and Merck's Januvia commence in the second half.